These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 24861776)

  • 21. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
    Burris HA
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
    Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG
    PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the PI3K-AKT-mTOR signaling network in cancer.
    Khan KH; Yap TA; Yan L; Cunningham D
    Chin J Cancer; 2013 May; 32(5):253-65. PubMed ID: 23642907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adipocyte-conditioned medium induces tamoxifen resistance by activating PI3K/Akt/mTOR pathway in estrogen receptor-positive breast cancer cells.
    Nakatsuji M; Fujimori K
    Biochim Biophys Acta Mol Cell Res; 2024 Oct; 1871(7):119821. PubMed ID: 39159684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular mechanisms regulating the hormone sensitivity of breast cancer.
    Tokunaga E; Hisamatsu Y; Tanaka K; Yamashita N; Saeki H; Oki E; Kitao H; Maehara Y
    Cancer Sci; 2014 Nov; 105(11):1377-83. PubMed ID: 25155268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer.
    Nunnery SE; Mayer IA
    Drugs; 2020 Nov; 80(16):1685-1697. PubMed ID: 32894420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
    Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
    Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015].
    Vanacker H; Bally O; Kassem L; Tredan O; Heudel P; Bachelot T
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S47-52. PubMed ID: 26118876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions.
    Malaguti P; Vari S; Cognetti F; Fabi A
    Anticancer Res; 2013 Jan; 33(1):21-8. PubMed ID: 23267124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. mTOR inhibitors: changing landscape of endocrine-resistant breast cancer.
    Chumsri S; Sabnis G; Tkaczuk K; Brodie A
    Future Oncol; 2014 Feb; 10(3):443-56. PubMed ID: 24559450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.
    Lauring J; Park BH; Wolff AC
    J Natl Compr Canc Netw; 2013 Jun; 11(6):670-8. PubMed ID: 23744866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones.
    Cavazzoni A; Bonelli MA; Fumarola C; La Monica S; Airoud K; Bertoni R; Alfieri RR; Galetti M; Tramonti S; Galvani E; Harris AL; Martin LA; Andreis D; Bottini A; Generali D; Petronini PG
    Cancer Lett; 2012 Oct; 323(1):77-87. PubMed ID: 22484466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.
    Mohd Sharial MSN; Crown J; Hennessy BT
    Ann Oncol; 2012 Dec; 23(12):3007-3016. PubMed ID: 22865781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy.
    Tan J; Yu Q
    Chin J Cancer; 2013 Jul; 32(7):376-9. PubMed ID: 23668928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
    Beeram M; Tan QT; Tekmal RR; Russell D; Middleton A; DeGraffenried LA
    Ann Oncol; 2007 Aug; 18(8):1323-8. PubMed ID: 17693645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.
    Gonzalez-Angulo AM; Blumenschein GR
    Cancer Treat Rev; 2013 Jun; 39(4):313-20. PubMed ID: 23218708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer.
    Alves CL; Ditzel HJ
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.